Biotech PE vs Healthcare PE
I know that historically healthcare buyout PE firms have focused on HCIT or HC Services. Recently have seen biopharma PE more often particularly with the life sciences divisions of many MFs. Curious if this is more a growth/VC arm or are traditional buyouts becoming more common in the biopharma space? In terms of recruiting do they look for M.D.s or people with PhDs in biotech or is that an option for anyone working in Biopharma IB? Would appreciate any insight on this!
There are definitely some PE firms that play in biotech, but for the most part it’s a capital intensive industry with a binary outcome profile - you’re going to burn a shit ton of cash and either make a ton of money or lose it all, with minimal middle ground. You do see the more advanced stages hit the buyout space (once there’s an existing product) or occasionally going to royalties-focused funds
PhD (or MS / MD) is a leg up and required at some funds, but it’s also possible to do if you come from life sciences banking (or, rarely, equity research)
Qui nam voluptatem voluptatibus necessitatibus excepturi. Sed ab ut quas tempora. Eligendi cupiditate qui nobis eum at error. Fugiat tempora ut ut et voluptates cupiditate. Natus aspernatur quisquam quam aut.
Nulla tempora sed debitis. Voluptate veniam voluptas sit quidem odit cupiditate. Natus recusandae quia eos possimus dolorem ullam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...